

Response to Letter to the Editor: “Hypertension and Type 2 Diabetes Are Associated With Decreased Inhibition of Dipeptidyl Peptidase-4 by Sitagliptin”

Jessica R. Wilson,¹⁻³ Megan M. Shuey,¹ Nancy J. Brown,¹ and Jessica K. Devin^{2,4}

¹Division of Clinical Pharmacology, Vanderbilt Department of Medicine, Nashville, Tennessee; ²Division of Endocrinology, Diabetes, and Metabolism, Vanderbilt Department of Medicine, Nashville, Tennessee; ³Division of Endocrinology, Diabetes and Metabolism, University of Pennsylvania Department of Medicine, Philadelphia, Pennsylvania; and ⁴UCHealth Endocrinology, Yampa Valley Medical Center, Steamboat Springs, Colorado

ORCID numbers: 0000-0001-7109-3142 (N. J. Brown).

© Endocrine Society 2020.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

We appreciate Dr. Taylor’s thorough review of the history of dipeptidyl peptidase-4 (DPP4) activity measurements. Although dilution of sitagliptin could account for the slightly diminished inhibition of DPP4 activity in controls compared with that previously reported, it could not account for the difference between controls and obese hypertensives reported in the paper, as DPP4 activity was measured using the same methodology in all groups. In addition, we reported an inverse correlation between body mass index and DPP4 activity, suggesting the effect may have been related to the volume of distribution of sitagliptin.

ACKNOWLEDGEMENTS

Financial Support: This work was supported by National Institutes of Health (NIH) Grants T32GM007569 (to J.R.W.), F31DK108444 (to M.M.S.), and R01HL125426 (to N.J.B.); American Heart Association (AHA) Grant 17SFRN33520017; and Grant K23HL119602 NIH/NHLBI (to J.K.D.). This work was also supported by Clinical and Translational Science Award (CTSA) Grant UL2TR000445 (National Institutes of Health).

Additional Information:

Correspondence: Nancy J. Brown, MD, Vanderbilt Department of Medicine, Division of Clinical Pharmacology. E-mail: nancy.j.brown@VUMC.org.

Disclosure Summary: The authors have nothing to disclose.

Abbreviation: DPP4, dipeptidyl peptidase-4.

Received 14 January 2020

Accepted 27 January 2020

First Published Online 29 February 2020

Corrected and Typeset: 29 February 2020

March 2020 | Vol. 4, Iss. 3
doi: 10.1210/jendso/bvaa006 | Journal of the Endocrine Society | 1–1